Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 91

Cited In for PubMed (Select 8871587)

1.

Electron Transport Disturbances and Neurodegeneration: From Albert Szent-Györgyi's Concept (Szeged) till Novel Approaches to Boost Mitochondrial Bioenergetics.

Szalárdy L, Zádori D, Klivényi P, Toldi J, Vécsei L.

Oxid Med Cell Longev. 2015;2015:498401. doi: 10.1155/2015/498401. Epub 2015 Aug 2. Review.

2.

An Essential Role of the Mitochondrial Electron Transport Chain in Cell Proliferation Is to Enable Aspartate Synthesis.

Birsoy K, Wang T, Chen WW, Freinkman E, Abu-Remaileh M, Sabatini DM.

Cell. 2015 Jul 30;162(3):540-51. doi: 10.1016/j.cell.2015.07.016.

PMID:
26232224
3.

Mitochondrial Morphology and Fundamental Parameters of the Mitochondrial Respiratory Chain Are Altered in Caenorhabditis elegans Strains Deficient in Mitochondrial Dynamics and Homeostasis Processes.

Luz AL, Rooney JP, Kubik LL, Gonzalez CP, Song DH, Meyer JN.

PLoS One. 2015 Jun 24;10(6):e0130940. doi: 10.1371/journal.pone.0130940. eCollection 2015.

4.

Parkinson's disease as a result of aging.

Rodriguez M, Rodriguez-Sabate C, Morales I, Sanchez A, Sabate M.

Aging Cell. 2015 Jun;14(3):293-308. doi: 10.1111/acel.12312. Epub 2015 Feb 9.

5.

Cytoplasmic hybrid (cybrid) cell lines as a practical model for mitochondriopathies.

Wilkins HM, Carl SM, Swerdlow RH.

Redox Biol. 2014 Apr 1;2C:619-631. doi: 10.1016/j.redox.2014.03.006. [Epub ahead of print] Review.

6.

Mitochondrial polymorphism A10398G and Haplogroup I are associated with Fuchs' endothelial corneal dystrophy.

Li YJ, Minear MA, Qin X, Rimmler J, Hauser MA, Allingham RR, Igo RP, Lass JH, Iyengar SK, Klintworth GK, Afshari NA, Gregory SG; FECD Genetics Consortium.

Invest Ophthalmol Vis Sci. 2014 Jun 10;55(7):4577-84. doi: 10.1167/iovs.13-13517.

7.

The interplay between iron accumulation, mitochondrial dysfunction, and inflammation during the execution step of neurodegenerative disorders.

Urrutia PJ, Mena NP, Núñez MT.

Front Pharmacol. 2014 Mar 10;5:38. doi: 10.3389/fphar.2014.00038. eCollection 2014. Review.

8.

The impact of mitochondrial DNA and nuclear genes related to mitochondrial functioning on the risk of Parkinson's disease.

Gaweda-Walerych K, Zekanowski C.

Curr Genomics. 2013 Dec;14(8):543-59. doi: 10.2174/1389202914666131210211033.

9.

A phenotypic model recapitulating the neuropathology of Parkinson's disease.

Ferris CF, Marella M, Smerkers B, Barchet TM, Gershman B, Matsuno-Yagi A, Yagi T.

Brain Behav. 2013 Jul;3(4):351-66. doi: 10.1002/brb3.138. Epub 2013 Apr 17.

10.

The Role of skn-1 in methylmercury-induced latent dopaminergic neurodegeneration.

Martinez-Finley EJ, Caito S, Slaughter JC, Aschner M.

Neurochem Res. 2013 Dec;38(12):2650-60. doi: 10.1007/s11064-013-1183-0. Epub 2013 Nov 6.

11.

Rapamycin drives selection against a pathogenic heteroplasmic mitochondrial DNA mutation.

Dai Y, Zheng K, Clark J, Swerdlow RH, Pulst SM, Sutton JP, Shinobu LA, Simon DK.

Hum Mol Genet. 2014 Feb 1;23(3):637-47. doi: 10.1093/hmg/ddt450. Epub 2013 Sep 18.

12.

Mitochondria-targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes.

Jin H, Kanthasamy A, Ghosh A, Anantharam V, Kalyanaraman B, Kanthasamy AG.

Biochim Biophys Acta. 2014 Aug;1842(8):1282-94. doi: 10.1016/j.bbadis.2013.09.007. Epub 2013 Sep 20. Review.

13.

Bioenergetic medicine.

Swerdlow RH.

Br J Pharmacol. 2014 Apr;171(8):1854-69. doi: 10.1111/bph.12394. Review.

14.

Modeling Alzheimer's disease: from past to future.

Saraceno C, Musardo S, Marcello E, Pelucchi S, Luca MD.

Front Pharmacol. 2013 Jun 19;4:77. doi: 10.3389/fphar.2013.00077. eCollection 2013.

15.

Bioenergetic flux, mitochondrial mass and mitochondrial morphology dynamics in AD and MCI cybrid cell lines.

Silva DF, Selfridge JE, Lu J, E L, Roy N, Hutfles L, Burns JM, Michaelis EK, Yan S, Cardoso SM, Swerdlow RH.

Hum Mol Genet. 2013 Oct 1;22(19):3931-46. doi: 10.1093/hmg/ddt247. Epub 2013 Jun 4.

16.

Mitochondrial quality, dynamics and functional capacity in Parkinson's disease cybrid cell lines selected for Lewy body expression.

Cronin-Furman EN, Borland MK, Bergquist KE, Bennett JP Jr, Trimmer PA.

Mol Neurodegener. 2013 Jan 26;8:6. doi: 10.1186/1750-1326-8-6.

17.

MPTP mouse models of Parkinson's disease: an update.

Meredith GE, Rademacher DJ.

J Parkinsons Dis. 2011;1(1):19-33. doi: 10.3233/JPD-2011-11023. Review.

18.

Mitochondrial neuronal uncoupling proteins: a target for potential disease-modification in Parkinson's disease.

Ho PW, Ho JW, Liu HF, So DH, Tse ZH, Chan KH, Ramsden DB, Ho SL.

Transl Neurodegener. 2012 Jan 13;1(1):3. doi: 10.1186/2047-9158-1-3.

19.

Evaluating mitochondrial DNA variation in autism spectrum disorders.

Hadjixenofontos A, Schmidt MA, Whitehead PL, Konidari I, Hedges DJ, Wright HH, Abramson RK, Menon R, Williams SM, Cuccaro ML, Haines JL, Gilbert JR, Pericak-Vance MA, Martin ER, McCauley JL.

Ann Hum Genet. 2013 Jan;77(1):9-21. doi: 10.1111/j.1469-1809.2012.00736.x. Epub 2012 Nov 6.

20.

Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism.

Hauser DN, Hastings TG.

Neurobiol Dis. 2013 Mar;51:35-42. doi: 10.1016/j.nbd.2012.10.011. Epub 2012 Oct 12. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk